Risk Materials

Educational Risk Minimisation Materials to help reduce the risk associated with using this medicine.

Eliquis (apixaban) Healthcare Professional Risk Minimisation Material Website

This website is for healthcare professionals (HCPs) and is based on the paper and electronic version of the Eliquis (apixaban) Prescriber Guide. The website contains information for HCPs to be aware of before prescribing apixaban and in particular is aimed at increasing awareness about the potential risk of bleeding with apixaban. The website includes information on increased bleeding risks with apixaban, guidance on the use of apixaban in patients undergoing surgery and invasive procedures, therapy management, management of overdose and haemorrhage. The site can be viewed using Firefox, Google Chrome or recent versions of Internet Explorer.

For Healthcare Professionals

Eliquis (apixaban) Patient Alert Card

Patients prescribed Eliquis (apixaban) will receive a Patient Alert Card in the medication pack with the package leaflet. The card contains important safety information including the importance of taking apixaban regularly as instructed by the doctor, the main signs and symptoms of bleeding and when to seek medical attention. As the card contains important information, the patient should be instructed to carry the Patient Alert Card at all times and show it to every healthcare professional including pharmacists. The card was last updated in April 2020 to include the instruction that patients should also inform their doctor if they are having an invasive procedure. If you would like a hard copy of the Patient Alert Card posted out to you, please contact BMS Medical Information (telephone: 0800 731 1736; e-mail: [email protected]).

Eliquis (apixaban) Prescriber Guide

This risk minimisation material is for Eliquis for all indications. Please ensure that you are familiar with this material before prescribing Eliquis as it contains important safety information on the potential risk of bleeding during treatment with Eliquis and provides guidance on how to manage that risk. Updates made to the Prescriber Guide in April 2020 reflect changes to the Summary of Product Characteristics (SPC) for apixaban 2.5 mg and 5 mg tablets on drug-drug interactions with fluconazole and concomitant use of apixaban with medicinal products that inhibit platelet aggregation, which may lead to an increased risk of bleeding. If you would like to obtain hard copies of the Eliquis Prescriber Guide and/or Patient Alert Card and/or SPCs, please contact Bristol-Myers Squibb Medical Information (telephone: 0800 731 1736; Email: [email protected]) with your specific request. Risk minimisation materials can only be delivered to UK registered healthcare premises.

For Healthcare Professionals

Send us feedback

If you would like to make a comment or send us feedback on this material, click here.